NASDAQ:IPHA

Innate Pharma Competitors

$4.30

-0.09 (-2.05 %)

(As of 03/4/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.25

Now: $4.30▼

$4.46

50-Day Range

$4.09

MA: $4.43▼

$4.83

52-Week Range

$3.30

Now: $4.30▼

$8.23

Volume6,078 shs

Average Volume57,402 shs

Market Capitalization$339.62 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Innate Pharma (NASDAQ:IPHA) Vs. ATRA, ALEC, IMVT, PCVX, CHRS, and MESO

Should you be buying IPHA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Innate Pharma, including Atara Biotherapeutics (ATRA), Alector (ALEC), Immunovant (IMVT), Vaxcyte (PCVX), Coherus BioSciences (CHRS), and Mesoblast (MESO).

Innate Pharma vs. Atara Biotherapeutics Stock

Atara Biotherapeutics (NASDAQ:ATRA) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider and Institutional Ownership

2.1% of Innate Pharma shares are owned by institutional investors. 4.3% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Atara Biotherapeutics and Innate Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	0	3	7	0	2.70
Innate Pharma	0	3	1	0	2.25

Atara Biotherapeutics currently has a consensus target price of $35.8750, indicating a potential upside of 125.77%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atara Biotherapeutics is more favorable than Innate Pharma.

Profitability

This table compares Atara Biotherapeutics and Innate Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	N/A	-94.86%	-82.17%
Innate Pharma	N/A	N/A	N/A

Earnings & Valuation

This table compares Atara Biotherapeutics and Innate Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	N/A	N/A	$-290,980,000.00	($5.67)	-2.80
Innate Pharma	$96.12 million	3.53	$-23,250,000.00	($0.34)	-12.65

Innate Pharma has higher revenue and earnings than Atara Biotherapeutics. Innate Pharma is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Innate Pharma beats Atara Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Innate Pharma vs. Alector Stock

Alector (NASDAQ:ALEC) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider and Institutional Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alector and Innate Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alector	-757.78%	-53.86%	-31.44%
Innate Pharma	N/A	N/A	N/A

Earnings & Valuation

This table compares Alector and Innate Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.22 million	60.94	$-105,390,000.00	($1.71)	-9.50
Innate Pharma	$96.12 million	3.53	$-23,250,000.00	($0.34)	-12.65

Innate Pharma has higher revenue and earnings than Alector. Innate Pharma is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alector and Innate Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	0	0	6	0	3.00
Innate Pharma	0	3	1	0	2.25

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Alector is more favorable than Innate Pharma.

Summary

Alector beats Innate Pharma on 7 of the 13 factors compared between the two stocks.

Innate Pharma vs. Immunovant Stock

Immunovant (NASDAQ:IMVT) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

40.2% of Immunovant shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. 0.2% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Immunovant and Innate Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-34.80%	-32.38%
Innate Pharma	N/A	N/A	N/A

Earnings and Valuation

This table compares Immunovant and Innate Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	$-66,390,000.00	($1.54)	-8.49
Innate Pharma	$96.12 million	3.53	$-23,250,000.00	($0.34)	-12.65

Innate Pharma has higher revenue and earnings than Immunovant. Innate Pharma is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Immunovant and Innate Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0	1	14	0	2.93
Innate Pharma	0	3	1	0	2.25

Immunovant currently has a consensus target price of $45.60, indicating a potential upside of 248.62%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Immunovant's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunovant is more favorable than Innate Pharma.

Summary

Immunovant beats Innate Pharma on 6 of the 11 factors compared between the two stocks.

Innate Pharma vs. Vaxcyte Stock

Vaxcyte (NASDAQ:PCVX) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Vaxcyte and Innate Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	N/A	N/A
Innate Pharma	N/A	N/A	N/A

Earnings and Valuation

This table compares Vaxcyte and Innate Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	$-50,270,000.00	N/A	N/A
Innate Pharma	$96.12 million	3.53	$-23,250,000.00	($0.34)	-12.65

Innate Pharma has higher revenue and earnings than Vaxcyte.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vaxcyte and Innate Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	4	0	3.00
Innate Pharma	0	3	1	0	2.25

Vaxcyte currently has a consensus target price of $48.00, indicating a potential upside of 103.22%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Innate Pharma.

Summary

Vaxcyte beats Innate Pharma on 4 of the 6 factors compared between the two stocks.

Innate Pharma vs. Coherus BioSciences Stock

Coherus BioSciences (NASDAQ:CHRS) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

2.1% of Innate Pharma shares are owned by institutional investors. 15.9% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Coherus BioSciences and Innate Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coherus BioSciences	33.06%	90.98%	27.33%
Innate Pharma	N/A	N/A	N/A

Earnings and Valuation

This table compares Coherus BioSciences and Innate Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus BioSciences	$356.07 million	3.12	$89.83 million	$1.23	12.39
Innate Pharma	$96.12 million	3.53	$-23,250,000.00	($0.34)	-12.65

Coherus BioSciences has higher revenue and earnings than Innate Pharma. Innate Pharma is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Coherus BioSciences and Innate Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus BioSciences	0	1	5	0	2.83
Innate Pharma	0	3	1	0	2.25

Coherus BioSciences currently has a consensus target price of $27.8571, indicating a potential upside of 82.73%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Coherus BioSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Coherus BioSciences is more favorable than Innate Pharma.

Summary

Coherus BioSciences beats Innate Pharma on 11 of the 13 factors compared between the two stocks.

Innate Pharma vs. Mesoblast Stock

Mesoblast (NASDAQ:MESO) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Insider & Institutional Ownership

2.8% of Mesoblast shares are owned by institutional investors. Comparatively, 2.1% of Innate Pharma shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Mesoblast and Innate Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	-591.00%	-18.69%	-13.85%
Innate Pharma	N/A	N/A	N/A

Earnings and Valuation

This table compares Mesoblast and Innate Pharma's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$32.16 million	33.54	$-77,940,000.00	($0.74)	-12.41
Innate Pharma	$96.12 million	3.53	$-23,250,000.00	($0.34)	-12.65

Innate Pharma has higher revenue and earnings than Mesoblast. Innate Pharma is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Mesoblast and Innate Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1	3	2	0	2.17
Innate Pharma	0	3	1	0	2.25

Mesoblast currently has a consensus target price of $14.55, indicating a potential upside of 58.50%. Innate Pharma has a consensus target price of $7.5833, indicating a potential upside of 76.36%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Innate Pharma is more favorable than Mesoblast.

Summary

Innate Pharma beats Mesoblast on 8 of the 13 factors compared between the two stocks.